New research reveals that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end conventional lifestyle programs.
Published data in a prominent medical journal demonstrates that while obese people frequently drop substantial amounts of their body weight while using the jabs, the mass returns at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such drugs need to be informed of the risk of quick rebound weight gain when the therapy concludes," stated expert Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment mass within about one and a half years.
Analyzing Treatments
The study, which examined 37 of studies involving thousands of patients, compared the outcomes of these new drugs with conventional dieting.
The team emphasize that people who shed pounds through lifestyle changes alone typically see a more gradual creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Experts propose the way of the drugs accounts for the heightened rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing the hormone concentrations far above than the body's typical production may cause the system to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication results in appetite is no longer kept in check, making binge eating a significant risk."
A Lifelong Condition?
The NHS advise the injections for people with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, given the high risk of weight regain, the treatment might need to be long-term.
This view is reinforced by drug manufacturers, who state that the findings "emphasize the persistent character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Experiences
Users who have stopped the jabs describe a powerful resurgence of hunger.
"It felt as if a switch flipping and you become extremely hungry," recalled a patient.
The struggle is compounded if users have not established lasting dietary or behavioural changes during treatment.
Growing Use
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is higher among females than men.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
Finally, experts emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and maintained weight loss relies on ongoing behavioural support.
